Patents
Literature
Patsnap Copilot is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Patsnap Copilot

118results about How to "Stable drug release" patented technology

Core-shell type pre-charged chemotherapy medicine embolization microsphere and preparation method thereof

The invention provides a core-shell type pre-charged chemotherapy medicine embolization microsphere and a preparation method thereof. The method comprises the following steps of using water/oil/water(W/O/W) complex emulsion type or oil/water/oil (O/W/O) complex emulsion type emulsified micro liquid drips as templates; coating tiny liquid drips containing medicine into outer layer liquid drips; high molecular polymers in the inner and outer layer liquid drips are converted through measures such as physical measures and chemical measures to form an inner layer core and an outer layer shell. Theformed core-shell structure medicine microsphere is formed by polymers of two-layer structures; the inner core contains medicine; the outer shell is favorable for maintaining the activity of the inner core medicine; the stable medicine release is realized; the sudden release is prevented; the safety is enhanced. The medicine carried microsphere prepared by the method has the advantages that the particle diameter range is 10 to 1000 micrometers; the sphere degree is good; the particle diameter is uniform; (the dimension deviation is 5 percent); the medicine encapsulation rate is high; the structure/carried medicine is controllable; meanwhile, the preparation method of the pre-charged chemotherapy medicine embolization microsphere can provide a novel idea for the clinic application study ofthe transcatheter arterial embolization.
Owner:ENERGY RES INST OF SHANDONG ACAD OF SCI

Microsphere preparation encapsulating hydrophilic medicine and preparation method thereof

The invention discloses a microsphere preparation encapsulating a hydrophilic medicine, and the microsphere preparation comprises the following components in percentage by weight: a hydrophilic medicine 0.1-40%, methoxy poly(ethylene glycol)-poly(lactic acid) block copolymers 0.1-99%, and poly(lactic acid) or poly(lactic acid-glycollic acid) copolymers 0.1-99%. The microsphere preparation has round and intact surface, uniform and controllable particle diameter, high encapsulation rate, and controllable drug release behaviors. The invention also discloses a preparation method of the microsphere preparation encapsulating the hydrophilic medicine, and the preparation method has simple process and good controllability and comprises the following steps: adding a water solution of the hydrophilic medicine into an organic solution of the methoxy poly(ethylene glycol)-poly(lactic acid) block copolymers, and vortexing to form water-in-oil type primary emulsion; adding the primary emulsion intoliquid paraffin containing emulsifier I, and vortexing to form water-in-oil type multiple emulsion; and adding the multiple emulsion into liquid paraffin containing emulsifier II, continuing stirringfor 4-24 h, centrifuging, collecting pellets, washing, and drying to obtain the microsphere preparation encapsulating the hydrophilic medicine.
Owner:ZHEJIANG UNIV

Preparation method of paliperidone sustained release microsphere injection

The invention discloses a preparation method of a paliperidone sustained release microsphere injection. The preparation technology comprises the following steps: (1) paliperidone and an acid anhydrides reagent are respectively dissolved in a solvent to be subjected to esterification reaction under the effect of an alkaline catalyst; (2) the esterification product obtained in the step (1) is dissolved in anhydrous dichloromethane to be subjected to acylation reaction with the added acylation reagent with DMF (N, N- dimethylformamide) being the catalyst; (3) the acylated paliperidone is subjected to esterification reaction with polylactic acid (PLA) through chemical bond bonding; (4) paliperidone sustained release microspheres are prepared by adopting solvent evaporation method, and the paliperidone sustained release microspheres are prepared into the microsphere injection after being cooled and dried. The preparation method is safe to operate, mild in reaction condition and simple and clear in steps; the total yield reaches 50% or above; the particle sizes of the obtained paliperidone microspheres are 30-50 micron; the paliperidone sustained release microsphere injection provided by the invention is high in drug loading capacity, stable in drug release, long in drug release time and good in sustained release effect.
Owner:HEILONGJIANG UNIV

Mifepristone shell-type vaginal ring preparation and application

The invention relates to mifepristone shell-type vaginal ring preparation and application. A miferprisone shell-type vaginal ring comprises, by weight, 1.0-6.0% of mifepristone, 0.5-3.0% of medicine dispersion carriers, 0.3-2.0% of additives and 89.0-98.2% of medical polymer controlled release materials. Firstly, a solid dispersion technology is adopted for improving the solubility in water and release degree in vitro of the mifepristone, then a method of mold pressing vulcanization forming is adopted for preparing the mifepristone shell-type vaginal ring, the inner layer is a vacancy silicon rubber skeleton layer, the middle is a medicated layer, and the outmost layer is a controlled release film. By the implementation of the mifepristone shell-type vaginal ring preparation and application, the vaginal ring can release the mifepristone within 21 days at almost constant speed slowly and continuously for a long time, so that the medicine can be released more stably, the first-pass effect and gastrointestinal reaction caused by oral medication of the mifepriston are avoided, and the biological availability of the medicine and medication compliance of a patient are improved. The vaginal ring can be used for routine contraception and treating gynecological diseases such as the endometriosis and the uterine fibroid.
Owner:NAT RES INST FOR FAMILY PLANNING

Detection method of medicament for treating angina pectoris

InactiveCN102768247AExcellent disintegration and solubilityThe curative effect is fastComponent separationCardiovascular disorderAnginaCoronary heart disease
The invention provides a detection method of a medicament for treating angina pectoris. According to the detection method, ginsenoside Rg1, ginsenoside Re and ginsenoside Rb1 in the medicament are detected by high performance liquid chromatography. Conditions of the high performance liquid chromatography comprise: octadecylsilane bonded silica gel is used as a chromatographic column for a filler; and an acetonitrile solution is used as a mobile phase A and water is used as a mobile phase B for gradient elution. The gradient elution process is as follows: during the first 25 minutes, the mobile phase A acetonitrile solution is 15% by volume and the mobile phase B water is 85% by volume; from the 25th minute to the 70th minute, the mobile phase A acetonitrile solution is 15-22% by volume and the mobile phase B water is 85-78% by volume; from the 70th minute to the 80th minute, the mobile phase A acetonitrile solution is 22-30% by volume and the mobile phase B water is 78-70% by volume; from the 80th minute to 105th minute, the mobile phase A acetonitrile solution is 30-40% by volume and the mobile phase B water is 70-60% by volume; and from the 105th minute to 120th minute, the mobile phase A acetonitrile solution is 40-15% by volume and the mobile phase B water is 60-85% by volume.
Owner:梁丽
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products